Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Swart

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Rheumatology (Oxford, England)|October 6, 2021
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registriesLianne Kearsley-Fleet, Jens Klotsche, Joeri W van Straalen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up StudyNienke M Ter Haar, E H Pieter van Dijkhuizen, Joost F Swart, et al.
Expert Review of Clinical Immunology|May 5, 2026
What is the best way to plan a 12-months clinical drug trial in JIA associated uveitisIvan Foeldvari, Ameenat Solebo, Sheila T Angeles-Han, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
The Journal of Rheumatology|August 17, 2011
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010Marieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Plos One|June 6, 2019
Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMOA V Ramanan, L V Hampson, H Lythgoe, et al.
Vaccine|January 23, 2024
Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort studyMohamad Hamad Saied, Joeri W van Straalen, Sytze de Roock, et al.
The Journal of Rheumatology|February 2, 2022
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild RegistryGabriella Giancane, Riccardo Papa, Sebastiaan Vastert, et al.
Pediatric Rheumatology Online Journal|April 8, 2021
Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritisAnouk Verwoerd, Wineke Armbrust, Katherine Cowan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 2, 2022
Development and External Validation of a Model Predicting New-Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic ArthritisJoeri W van Straalen, Lianne Kearsley-Fleet, Jens Klotsche, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Rheumatology (Oxford, England)|October 6, 2021
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registriesLianne Kearsley-Fleet, Jens Klotsche, Joeri W van Straalen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up StudyNienke M Ter Haar, E H Pieter van Dijkhuizen, Joost F Swart, et al.
Expert Review of Clinical Immunology|May 5, 2026
What is the best way to plan a 12-months clinical drug trial in JIA associated uveitisIvan Foeldvari, Ameenat Solebo, Sheila T Angeles-Han, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
The Journal of Rheumatology|August 17, 2011
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010Marieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Plos One|June 6, 2019
Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMOA V Ramanan, L V Hampson, H Lythgoe, et al.
Vaccine|January 23, 2024
Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort studyMohamad Hamad Saied, Joeri W van Straalen, Sytze de Roock, et al.
The Journal of Rheumatology|February 2, 2022
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild RegistryGabriella Giancane, Riccardo Papa, Sebastiaan Vastert, et al.
Pediatric Rheumatology Online Journal|April 8, 2021
Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritisAnouk Verwoerd, Wineke Armbrust, Katherine Cowan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 2, 2022
Development and External Validation of a Model Predicting New-Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic ArthritisJoeri W van Straalen, Lianne Kearsley-Fleet, Jens Klotsche, et al.
Pageof 12